Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8445356 | European Journal of Cancer | 2013 | 9 Pages |
Abstract
It is possible to generate evidence about drug use and cost-effectiveness in oncology practice to facilitate informed decision-making by both payers and physicians. This can improve quality of care and enhance the efficient allocation of resources. However, the optimal approach differs between drugs and their indications. Generating high-quality evidence requires active interdisciplinary collaboration. Patient registries can facilitate data collection but cannot resolve all issues. In most circumstances it is inevitable to use data-synthesis to obtain valid incremental cost-effectiveness estimates, but for some indications it will not be feasible to derive a valid and precise estimate.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Margreet G. Franken, Chantal W.M. van Gils, Jennifer G. Gaultney, Gepke O. Delwel, Wim Goettsch, Peter C. Huijgens, Adri Steenhoek, Cornelis J.A. Punt, Miriam Koopman, William K. Redekop, Carin A. Uyl-de Groot,